Dengue Virus-Polymersome Hybrid Nanovesicles for Advanced Drug Screening Using Real-Time Single Nanoparticle-Virus Tracking.
ACS Appl Mater Interfaces
; 12(6): 6876-6884, 2020 Feb 12.
Article
in En
| MEDLINE
| ID: mdl-31950828
ABSTRACT
Dengue virus (DENV) is a major infectious viral pathogen that affects millions of individuals worldwide every year, causing a potentially fatal syndrome, while no commercial antiviral drugs are yet available. To develop an antiviral against dengue fever, it is necessary to understand the relationship between DENV and host cells, which could provide a basis for viral dynamics and identification of inhibitory drug targets. In this study, we designed DiD-loaded and BODIPY-ceramide-encapsulated DENV-polymersome hybrid nanovesicles (DENVSomes) prepared by an extrusion method, which trigger red fluorescence in the endosome and green in the Golgi. DENVSome monitors the dynamics of host cell-virus interaction and tracking in living cells with novel state-of-the-art imaging technologies that show images at high resolution. Also, DENVSome can be exploited to screen whether candidate antiviral drugs interact with DENVs. Consequently, we successfully demonstrated that DENVSome is an efficient tool for tracking and unraveling the mechanisms of replication and drug screening for antiviral drugs of DENV.
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Dengue Virus
/
Drug Evaluation, Preclinical
Type of study:
Diagnostic_studies
/
Evaluation_studies
/
Screening_studies
Language:
En
Journal:
ACS Appl Mater Interfaces
Year:
2020
Type:
Article